mebendazole has been researched along with Glioblastoma in 3 studies
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although mebendazole (MBZ) has demonstrated antitumor activity in glioblastoma models, the drug has low aqueous solubility and therefore is poorly absorbed." | 7.96 | Preparation and Evaluation of Mebendazole Microemulsion for Intranasal Delivery: an Alternative Approach for Glioblastoma Treatment. ( Barragán-Aroche, F; Ganem-Rondero, A; García-López, P; Jung-Cook, H; Llaguno-Munive, M; López-Ramírez, S; Mayet-Cruz, L; Mena-Hernández, J; Rivera-Huerta, M, 2020) |
| "Mebendazole has been approved by the US Food and Drug Administration for parasitic infections, has a long track-record of safe human use, and was effective in our animal models with doses documented as safe in humans." | 5.37 | Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. ( Aprhys, CM; Bai, RY; Gallia, GL; Riggins, GJ; Staedtke, V, 2011) |
| "Although mebendazole (MBZ) has demonstrated antitumor activity in glioblastoma models, the drug has low aqueous solubility and therefore is poorly absorbed." | 3.96 | Preparation and Evaluation of Mebendazole Microemulsion for Intranasal Delivery: an Alternative Approach for Glioblastoma Treatment. ( Barragán-Aroche, F; Ganem-Rondero, A; García-López, P; Jung-Cook, H; Llaguno-Munive, M; López-Ramírez, S; Mayet-Cruz, L; Mena-Hernández, J; Rivera-Huerta, M, 2020) |
| "Mebendazole has been approved by the US Food and Drug Administration for parasitic infections, has a long track-record of safe human use, and was effective in our animal models with doses documented as safe in humans." | 1.37 | Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. ( Aprhys, CM; Bai, RY; Gallia, GL; Riggins, GJ; Staedtke, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Vítovcová, B | 1 |
| Skarková, V | 1 |
| Havelek, R | 1 |
| Soukup, J | 1 |
| Pande, A | 1 |
| Caltová, K | 1 |
| Rudolf, E | 1 |
| Mena-Hernández, J | 1 |
| Jung-Cook, H | 1 |
| Llaguno-Munive, M | 1 |
| García-López, P | 1 |
| Ganem-Rondero, A | 1 |
| López-Ramírez, S | 1 |
| Barragán-Aroche, F | 1 |
| Rivera-Huerta, M | 1 |
| Mayet-Cruz, L | 1 |
| Bai, RY | 1 |
| Staedtke, V | 1 |
| Aprhys, CM | 1 |
| Gallia, GL | 1 |
| Riggins, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors[NCT02644291] | Phase 1 | 16 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for mebendazole and Glioblastoma
| Article | Year |
|---|---|
Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest.
Topics: Adult; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prolif | 2023 |
Preparation and Evaluation of Mebendazole Microemulsion for Intranasal Delivery: an Alternative Approach for Glioblastoma Treatment.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Biological Availability; Brain Neoplasms | 2020 |
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
Topics: Animals; Antinematodal Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell | 2011 |
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
Topics: Animals; Antinematodal Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell | 2011 |
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
Topics: Animals; Antinematodal Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell | 2011 |
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
Topics: Animals; Antinematodal Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell | 2011 |